HC allows cancer patient to join plea on medicine prices

1. At a Glance

• Kerala High Court permitted a breast cancer patient from Malappuram to be impleaded in a pending suo motu case titled "In Re Exorbitant Pricing of Life Saving Patented Medicines", concerning the drug Ribociclib [3].
• Tests UPSC aspirants on intersection of IPR law (Patents Act, 1970), public health, and judicial activism — a recurring GS-II/GS-III theme (drug pricing, compulsory licensing, right to health under Article 21).
• Illustrates how Public Interest Litigation (PIL) and suo motu cognizance can survive the original petitioner's death and continue via impleadment of similarly-placed persons.
• Anchors a live debate on Section 84 of the Patents Act, 1970 (compulsory licensing) versus Section 92 (government use) as remedies for unaffordable patented medicines [3].

2. Why in the News

• The Kerala HC (Justice Harisankar V. Menon) allowed a new breast cancer patient to be impleaded in the ongoing Ribociclib pricing case, as reported by The Hindu, Chennai edition, 24 August 2026 [S1 — article excerpt].
• The original petition was filed by Sarojam Radhakrishnan, diagnosed with HR-Positive HER2-Negative Metastatic Breast Cancer, seeking directives for the government to take over the drug's patent and make it available at the lowest possible price [S1, S3].
• The court had earlier taken up the matter suo motu following the original petitioner's death in September 2022 [S1, S3].

3. Background & Evolution

• 2021: Sarojam Radhakrishnan (aged 68) diagnosed with breast cancer; prescribed Ribociclib, Letrozole, and Zoledronic Acid, costing ~₹63,480/month [2].
• February 2022: She approached Kerala HC seeking compulsory licensing or a government-use licence to make the medicines affordable [2].
• July 2022: Kerala HC directed the Department for Promotion of Industry and Internal Trade (DPIIT) to consider her representation for issuance of a compulsory licence for Ribociclib [4].
• September 2022: Petitioner died; HC converted the matter into a suo motu proceeding titled "In Re Exorbitant Pricing of Life Saving Patented Medicines" (16 September 2022) [2].
• Subsequent hearings: Court directed four expert bodies — National Cancer Institute (Jhajjar), Chittaranjan National Cancer Institute (Kolkata), Regional Cancer Centre (Thiruvananthapuram), and the Drugs Controller General of India (DCGI) — to opine on whether Palbociclib can be safely substituted for Ribociclib [2].
• 2026: A new breast cancer patient from Malappuram allowed to be impleaded in the same case, keeping the litigation alive [1].

4. Core Static Facts

5. Multi-Dimensional Analysis

Legal / Constitutional

• Centres on Section 84 Patents Act, 1970 — compulsory licensing grounds: reasonable requirements of the public not satisfied, invention not available at reasonably affordable price, or invention not worked in India [3].
• Only a generic manufacturer typically has locus standi to seek a compulsory licence under Section 84, raising a structural gap when courts try to invoke it via PIL/suo motu route [3].
• Case tests judicial power to convert a died-petitioner's plea into continuing suo motu litigation — procedural innovation in public health PILs.

Social

• Highlights catastrophic health expenditure from patented cancer drugs, disproportionately affecting middle/lower-income patients.
• Impleadment of a new patient shows the issue's breadth beyond one individual, reinforcing systemic (not case-specific) relief sought.

Economic

• Weighs patent-protected pricing/IP incentives for pharma innovation against affordability and access — a core TRIPS-era tension.
• Compulsory licensing viability constrained by absence of willing domestic generic manufacturers over nearly five years despite the case being live [3].

Governance / Ethical

• Raises questions on DPIIT's responsiveness to HC directions on compulsory licensing representations.
• Tests reliability of Form 27 working statements (patentee disclosures on whether/how a patent is worked in India) as evidentiary basis for CL applications [3].

Scientific/Technological

• Involves expert medical assessment (oncology bodies + DCGI) on therapeutic interchangeability of patented vs. alternative drugs (Ribociclib vs. Palbociclib) [2].

6. Recent Developments (last 12-18 months)

• 2026 (ongoing): Case remains active; Kerala HC has been seeking expert opinion from apex cancer institutes and DCGI on drug substitutability [2].
• 24 August 2026: HC allows a new breast cancer patient from Malappuram to be impleaded in the suo motu proceedings [1].
• SpicyIP commentary (July 2026) analyzing "To CL or Not to CL" debate around the case's structural limitations, indicating continued academic/legal attention through mid-2026 [3].

7. Prelims Hooks

• The suo motu case is titled "In Re Exorbitant Pricing of Life Saving Patented Medicines" — Kerala High Court [2].
• Drug at the centre of the case: Ribociclib, used for HR-Positive HER2-Negative Metastatic Breast Cancer, patented by Novartis [S1, S3].
• Section 84 of the Patents Act, 1970 governs compulsory licensing; Section 92 covers government use in emergencies [3].
• Nodal authority approached for compulsory licensing consideration: DPIIT (Department for Promotion of Industry and Internal Trade) [4].
• Alternative/comparator drug under expert review: Palbociclib [2].
• Expert bodies directed to give opinion: National Cancer Institute (Jhajjar), Chittaranjan National Cancer Institute (Kolkata), Regional Cancer Centre (Thiruvananthapuram), and DCGI [2].
• The original petitioner, Sarojam Radhakrishnan, died in September 2022; case converted to suo motu on 16 September 2022 [2].
• Only a generic manufacturer has locus standi to trigger Section 84 CL proceedings, not patients directly [3].
• The 24 August 2026 order allows impleadment of a new breast cancer patient from Malappuram, Kerala [1].
• Presiding judge in recent hearings: Justice Harisankar V. Menon [2].

8. Mains Relevance

• GS-II: Government policies and interventions for development in health sector; issues relating to development and management of Social Sector/Services (Health); Judiciary — PIL, suo motu jurisdiction, judicial activism.
• GS-II: Indian Constitution — Article 21 (Right to Health as part of Right to Life); statutory bodies (DPIIT).
• GS-III: Intellectual Property Rights (IPR) — Patents Act, 1970; compulsory licensing; balancing innovation incentives with public health access.
• Possible Mains question stems: 1. "Compulsory licensing under the Patents Act, 1970 remains a remedy more theoretical than practical." Critically examine this statement in light of recent judicial interventions on patented cancer drug pricing. 2. Discuss the role of suo motu jurisdiction of High Courts in ensuring access to affordable healthcare, citing recent examples. 3. Examine the tension between intellectual property protection and the constitutional right to health in India, with reference to patented life-saving medicines.

9. Related Topics to Study Next

• TRIPS Agreement & Doha Declaration on Public Health — international IP framework allowing compulsory licensing flexibilities.
• Natco Pharma v. Bayer (2012) — India's first and only granted compulsory licence case (Sorafenib/Nexavar), useful precedent comparison.
• Right to Health as part of Article 21 — jurisprudence on healthcare access as a fundamental right.
• National Pharmaceutical Pricing Authority (NPPA) and Drug Price Control Order (DPCO) — domestic drug pricing regulation mechanism.
• Ayushman Bharat–PM-JAY — government scheme addressing catastrophic health expenditure, relevant contrast to patent-price litigation route.
• Public Interest Litigation (PIL) and Suo Motu Cognizance — judicial mechanisms for social justice enforcement.
• Form 27 disclosures under Patents Act — patentee's statement of working, central to compulsory licensing evidentiary base.

10. Common Errors / Trap Areas

• Confusing Section 84 (compulsory licence, general grounds) with Section 92 (government use, national emergency/extreme urgency) — they are distinct provisions with different triggers.
• Assuming any patient/PIL petitioner has locus standi to seek compulsory licensing — in practice, only a willing generic manufacturer can apply under Section 84.
• Mixing up this case with the Natco v. Bayer (Sorafenib) case — that remains India's only successfully granted compulsory licence (2012); Ribociclib CL has NOT been granted, only "considered."
• Attributing the case to a Supreme Court ruling — this is a Kerala High Court matter, not Supreme Court.
• Assuming DPIIT has issued a compulsory licence — as of the latest reports, DPIIT has only been directed to consider the representation; no CL has been granted for Ribociclib.